Six Questions For TB Alliance CEO On Pretomanid And Pricing Issues

TB Alliance CEO Mel Spigelman outlines to Scrip the contours of the non-profit’s commercialization deal with Mylan for pretomanid, which is part of an oral combination regimen, and maintains that the $1/day pricing ask for the drug is based on flawed assumptions and not currently feasible.

Lung conference
Dr Mel Spigelman, President and CEO, TB Alliance • Source: TB Alliance

New treatments for drug-resistant tuberculosis (TB) have brought hope to patients, but access to these medicines and their pricing have been simmering issues in some resource-constrained high-burden markets.

The TB Alliance has been moving at a fast clip sewing up alliances to ensure an affordable, sustainable and competitive...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip